Cian Healthcare Limited

BSE: CHCL542678ISIN INE05BN01027

Healthcare
Pharmaceuticals

Share price

₹23.07+0.45 (+1.99%)

as of 28 Sep 2026

52W high: ₹23.07
52W low: ₹4.72
Off 52W high: 0.00%
1M return: +108.97%
3M return: —
6M return: —
1Y return: +383.65%
20D avg volume: 1,472
50 DMA: ₹9.97
200 DMA: ₹5.84

Key ratios Consolidated

Market cap: ₹57.68 Cr
Current price: ₹23.07
52W high / low: ₹23.07 / ₹4.72
Face value: ₹10.00
P/E: —
P/B: —
EPS (TTM): —
Book value / share: —
ROE: —
ROCE: -70.90%
Operating margin: —
Net margin: —
Debt / equity: —
Net debt: —
Interest cover: -109.38
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 53.7 days

Financials

Metric	FY26	FY25	FY24
Income statement
	28.30	30.80	—
	1.17	0.27	—
	39.35	44.81	—
	16.66	9.23	—
	0.23	4.08	—
	5.88	7.01	—
	0.21	2.92	—
	6.81	7.81	—
	-23.18	-26.00	—
	0.11	-0.02	—
	-23.29	-25.98	—
	0.00	-10.39	—
Key metrics
	-22.97	-23.08	—
	-81.20%	-74.90%	—
	-82.30%	-84.40%	—
	-70.90%	-55.50%	—
	-8.10%	—	—
	10.40%	—	—
	12.42	20.30	—
	-0.88	-0.80	—
	53.7	21.3	—
Balance sheet
	61.55	156.06	—
	22.88	70.84	—
	1.20	17.77	—
	12.64	17.39	—
	5.05	26.08	—
	3.56	4.28	—
	31.84	34.93	—
	13.52	41.68	—
	29.15	114.49	—
Cash flow
	20.51	20.71	—
	13.27	-0.26	—
	-50.35	-3.92	—
	-8.09	0.41	—

Metric	FY26	FY25	FY24
Income statement
	28.30	30.88	—
	1.16	0.25	—
	37.07	38.56	—
	16.66	18.58	—
	0.23	1.48	—
	5.88	6.65	—
	0.21	2.04	—
	6.32	6.97	—
	-20.91	-19.67	—
	0.11	-0.02	—
	-21.02	-19.66	—
	-3.09	-7.86	—
Key metrics
	-20.70	-17.63	—
	-73.10%	-57.10%	—
	-74.30%	-63.70%	—
	-54.20%	-39.10%	—
	-8.40%	—	—
	-6.90%	—	—
	20.45	20.62	—
	-0.97	-1.05	—
	126.0	86.2	—
Balance sheet
	48.22	142.68	—
	17.39	66.97	—
	1.13	17.66	—
	9.12	15.54	—
	4.59	25.62	—
	2.43	3.97	—
	22.01	23.32	—
	3.94	33.87	—
	10.04	97.59	—
Cash flow
	20.45	20.66	—
	13.36	-0.27	—
	-50.34	-3.46	—
	0.00	0.04	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY (TTM)	Profit YoY (TTM)	1Y return
Sun Pharmaceutical Industries Ltd.	4,41,467	1,840.00	36.43	17.90%	+11.41%	+16.54%	+15.97%
Divi's Laboratories Ltd.	2,53,031	9,531.50	86.51	19.00%	+16.35%	+26.84%	+67.50%
Torrent Pharmaceuticals Ltd.	1,85,210	4,869.40	85.91	9.10%	+32.85%	+7.69%	+36.65%
Zydus Lifesciences Limited	1,20,897	1,212.00	26.32	19.20%	+21.11%	-2.51%	+24.17%
Cipla Ltd.	1,12,203	1,388.90	33.44	14.90%	+1.85%	-37.69%	-7.34%
Laurus Labs Limited	1,08,711	2,012.00	99.67	19.70%	+22.62%	+114.95%	+141.62%
Dr. Reddy's Laboratories Ltd.	1,02,035	1,222.50	32.05	13.90%	-0.87%	-44.57%	-2.41%
Mankind Pharma Limited	1,00,764	2,439.55	48.73	13.70%	+13.75%	+8.10%	-1.69%
Aurobindo Pharma Ltd.	97,814	1,700.00	26.36	13.60%	+9.09%	+9.48%	+55.88%
Lupin Ltd	94,286	2,061.85	16.98	28.40%	+28.19%	+49.13%	+7.35%
Glenmark Pharmaceuticals ltd	65,928	2,336.00	36.67	16.20%	+32.94%	+138.48%	+18.56%
Alkem Laboratories Limited	61,804	5,169.10	28.04	18.80%	+13.36%	-5.52%	-4.73%
Biocon Ltd.	61,114	375.00	146.77	2.90%	+9.83%	-36.60%	+10.62%
Abbott India Ltd. S	56,861	26,758.85	35.22	41.90%	+6.29%	+11.18%	-10.07%
GlaxoSmithkline Pharmaceuticals Ltd.	49,091	2,897.85	45.96	55.40%	+5.75%	+12.41%	+8.51%
Ipca Laboratories Ltd.	48,704	1,920.05	35.42	16.40%	+10.59%	+67.91%	+40.09%
Gland Pharma Limited	47,779	2,895.50	42.31	13.70%	+17.57%	+46.55%	+47.68%
Ajanta Pharma Ltd.	44,118	3,530.60	38.87	29.40%	+20.19%	+22.04%	+43.30%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87%	+7.56%	+45.79%
Emcure Pharmaceuticals Limited	36,534	1,925.75	35.85	25.10%	+18.36%	+32.39%	+49.95%
Wockhardt Ltd	35,539	2,187.20	85.85	6.40%	+18.37%	+377.85%	+63.78%
Sai Life Sciences Limited	33,566	1,580.35	92.74	18.10%	—	—	+84.38%
Neuland Laboratories Limited.	27,498	21,433.15	55.24	23.10%	+78.33%	+182.59%	+53.59%
PIRAMAL PHARMA LIMITED	27,486	206.45	-87.64	0.80%	+0.78%	-419.79%	+9.96%
ACUTAAS CHEMICALS LIMITED	26,308	3,213.30	67.92	27.70%	+40.91%	+104.14%	+136.27%
Cian Healthcare Limited	58	23.07	—	-70.90%	—	—	+383.65%

Filings & corporate actions

Recent announcements

As per the Attachment.22 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
As per the Attachment.5 Sep 2026 · Company Update / General
As per the Attachment.4 Sep 2026 · Company Update / Newspaper Publication
As per the Attachment.4 Sep 2026 · AGM/EGM / AGM
The Annual Report for the Financial Year 2025-26 and Notice of the 23rd (Twenty-Third) Annual General Meeting (''AGM'') of the Company.4 Sep 2026 · Others / Reg. 34 (1) Annual Report
As per the Attachment.3 Sep 2026 · Company Update / Newspaper Publication
As per the Attachment2 Sep 2026 · Company Update / General
As per the Attachment.2 Sep 2026 · Company Update / General
Please find attached the disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015.27 Aug 2026 · Company Update / Resignation of Statutory Auditors
As per the Attachment22 Aug 2026 · Company Update / General
Please find attached Scrutinizer Report forming part of Outcome of Postal Ballot.10 Jul 2026 · AGM/EGM / Postal Ballot
Please find attached Outcome of Postal Ballot.10 Jul 2026 · AGM/EGM / Postal Ballot
As per the attachment.9 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
As per the attachment.4 Jul 2026 · Company Update / Cessation
As per the attachment.10 Jun 2026 · Company Update / Newspaper Publication
Disclosure pursuant to Regulation 30 of the SEBI Listing Regulations - Notice of Postal Ballot9 Jun 2026 · AGM/EGM / Postal Ballot
As per the Attachment30 May 2026 · Company Update / General
Cian Healthcare Limited, in its board meeting dated May 30, 2026, has approved the audited financial results (Standalone and Consolidated) along with Audit Report and Statement on Impact ....30 May 2026 · Result / Financial Results
Outcome of the Board Meeting of Cian Healthcare Limited held on May 30, 2026- Audited Financial Results (Standalone and Consolidated) for the half-year and Financial Year ended March 31, 2026.30 May 2026 · Board Meeting / Outcome of Board Meeting
Non-Applicability of Annual Secretarial Compliance Report for the Financial Year Ended March 31, 2026, as the Company is listed on the SME Platform of BSE Limited.29 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Cian Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve the Audited Financial Results ....26 May 2026 · Board Meeting / Board Meeting
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''><tr> <td>Sr. No.</td> <td>Particulars</td> <td>Details</td> ....20 Apr 2026 · Others / Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
As per the Disclosure attached.14 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
As per the Disclosure attached.31 Mar 2026 · Company Update / General
As per the Intimation attached.26 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
As per the attachment.21 Mar 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rajesh Jain18 Mar 2026 · Insider Trading / SAST / Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ananta Medicare Ltd18 Mar 2026 · Insider Trading / SAST / Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pradeep Kumar Jain18 Mar 2026 · Insider Trading / SAST / Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rajesh Jain & PACs17 Mar 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pradeep Kumar Jain & PACs17 Mar 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ananta Medicare Ltd & PACs17 Mar 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
as per the attachment16 Mar 2026 · Company Update / Code of Conduct under SEBI (PIT) Regulations, 2015
as per the attachment.16 Mar 2026 · Company Update / Change in Corporate Office Address
as per the attachment16 Mar 2026 · Company Update / General
as per the attachment16 Mar 2026 · Company Update / Change in Management
as per the attachment16 Mar 2026 · Company Update / Change in Directorate
As per the attachment.16 Mar 2026 · Company Update / Appointment of Company Secretary / Compliance Officer
As per the attachment.16 Mar 2026 · Others / Outcome without intimation
As per the attachment.11 Mar 2026 · Company Update / General

Corporate actions

Purpose	Ex date	Record date	Payment date
Resolution Plan -Suspension	21 Jan 2026	21 Jan 2026	—